Inhibition of lnc-COL6A1-6-Alleviated Osteogenic Differentiation of Valvular Interstitial Cells During Aortic Valve Calcification [0.03%]
lnc-COL6A1-6通过抑制瓣膜间质细胞成骨分化从而缓解主动脉瓣钙化的作用及机制研究
Ying Gu,Fan Yang,Quangong Zhao et al.
Ying Gu et al.
Background: Calcific aortic valve disease (CAVD) is a prevalent valvular heart disease characterized by the fibrocalcific remodeling of the aortic valves, leading to significant health issues among the elderly population worldwide. The aber...
Verteporfin Mitigates Isoproterenol-Induced Myocardial Hypertrophy by Attenuating IL-6/STAT3 in Cardiac Fibroblasts [0.03%]
verteporfin通过抑制心脏成纤维细胞中IL-6/STAT3信号减轻异丙肾上腺素诱导的心肌肥厚
Sunpeng Sheng,Lu Ding,Jinbiao Lai et al.
Sunpeng Sheng et al.
Background: Yes-associated protein (YAP) is a major downstream nuclear coactivator of the Hippo pathway and is activated during myocardial hypertrophy. Verteporfin, a YAP inhibitor, may serve as a potential treatment for myocardial hypertro...
Recent Advances in Renal Denervation Therapy and Novel Applications of High-Intensity Focused Ultrasound [0.03%]
肾交感神经消融治疗的最新进展及高强度聚焦超声的新应用
JunHao Wang,Yu Ma,Ximing Li
JunHao Wang
Hypertension constitutes a major risk factor for cardiovascular diseases. Globally, the management and control of hypertension remain suboptimal. At present, pharmacological intervention is a critical strategy for patients with hypertension...
The Application Value of Brain Natriuretic Peptide in the Prognostic Evaluation of Patients With Chronic Left Heart Failure [0.03%]
脑钠肽在慢性左心衰竭患者预后评估中的应用价值
Congling Xiang,Weier Zhou
Congling Xiang
This study explores the predictive utility of brain natriuretic peptide (BNP) levels in assessing outcomes for patients with chronic left heart failure (LHF). A cohort of 59 patients diagnosed with chronic LHF was compared to 59 healthy con...
Heart Rate Variability's Value in Predicting Out-of-Hospital Major Adverse Cardiovascular Events in Patients With Chronic Heart Failure [0.03%]
慢性心力衰竭患者中动态心率变异性预测院外主要不良心血管事件的价值
Li Men,Bingxin Chen,Long Yang et al.
Li Men et al.
Background: Chronic heart failure (CHF) involves changes in cardiac structure and function, along with extensive neuroendocrine adaptations and metabolic abnormalities. Heart rate variability (HRV) is a noninvasive measure of autonomic nerv...
Multicenter Study
Cardiovascular therapeutics. 2025 Aug 14:2025:6412775. DOI:10.1155/cdr/6412775 2025
Correlation and Influencing Factor Analysis Between Gal-3 and Recurrent Patients With Nonvalvular Atrial Fibrillation After Radiofrequency Ablation [0.03%]
血清Gal-3与射频消融复发性非瓣膜病房颤患者的关联及影响因素分析
Jing Lu,Fan Yang,Yu Gao et al.
Jing Lu et al.
Aims: This prospective cohort study was aimed at evaluating the association of galectin-3 (Gal-3) and other prognostic factors with atrial fibrillation (AF) recurrence in patients with nonvalvular AF undergoing radiofrequency catheter ablat...
Significance of APOB/APOA1 Ratio in the Prediction of Calcific Aortic Valve Disease [0.03%]
APOB/APOA1比值在钙化主动脉瓣疾病预测中的意义
Yuxing Wang,Ming Yu,Song Yang et al.
Yuxing Wang et al.
Background: Calcific aortic valve disease (CAVD) is a prevalent heart valve disease. The ratio of two apolipoproteins with distinct functions, Apolipoprotein B/Apolipoprotein A1 (APOB/APOA1), has been proposed as a novel assessment index fo...
Corrigendum to "Wogonin Inhibits Cardiac Hypertrophy by Activating Nrf-2-Mediated Antioxidant Responses" [0.03%]
黄芩素通过激活Nrf-2介导的抗氧化反应抑制心室肥大校正函
[This corrects the article DOI: 10.1155/2021/9995342.]. Copyright © 2025 Cardiovascular Therapeutics published by John Wiley & Sons Ltd.
Published Erratum
Cardiovascular therapeutics. 2025 Jul 31:2025:9864046. DOI:10.1155/cdr/9864046 2025
Eplerenone Inhibits Atrial Autonomic Nerve Remodeling in Atrial Fibrillation Through ERK1/2 MAPK Pathway [0.03%]
依普利酮通过ERK1/2 MAPK通路抑制房颤心房自主神经重塑
Wei Xu,Cheng-Yuan Yu,Ding-Yu Wang et al.
Wei Xu et al.
Atrial autonomic nerve system (ANS) remodeling plays an important role in atrial fibrillation (AF). Mineralocorticoid receptor antagonists (MRAs) have been proved to be effective in preventing atrial structural remodeling. However, the effe...
Rivaroxaban Ameliorates Sunitinib-Induced Injury of Cardiomyocytes via Repressing MAPK Signaling Pathway [0.03%]
利伐沙班通过抑制MAPK信号途径改善舒尼替引起的心肌细胞损伤
Ying Qian,Fang Yi
Ying Qian
Background: Sunitinib (SU) is used to treat kidney cancer. However, it can also cause cardiotoxicity. This study is performed to investigate whether rivaroxaban (RIV) attenuates SU-induced cardiotoxicity (SIC). Methods and Materials: AC16 c...